Alpha 2.0
Login Register
» Authors » Bernard Duysinx

Bernard Duysinx

Explore the profile of Bernard Duysinx including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 294
Followers 0
Related Specialties
Oncology
General Medicine
Pulmonary Medicine
Top 10 Co-Authors
Renaud Louis
Jean-Louis Corhay
Roland Hustinx
Vincent Heinen
Anne Sibille
Malik Hamaidia
Luc Willems
Pierre Lovinfosse
Philippe Coucke
Monique Henket
Published In
Rev Med Liege
Rev Med Suisse
Cancers (Basel)
Chest
Eur J Nucl Med Mol Imaging
Affiliations
Soon will be listed here.
Recent Articles
1.
Severe dual fungal infection after bispecific antibody therapy: A case of invasive aspergillosis and mucormycosis in immunocompromised patient
Sakalihasan S, Lifrange F, Czajkowski M, Goncette V, Duysinx B, Lovinfosse P, et al.
IDCases . 2025 Jan; 39():e02140. PMID: 39810812
Bispecific antibody is a new treatment for hematological disease, especially for lymphoma, myeloma and acute lymphoblastic leukemia. This class of treatment presents the same kind of side effect as CAR-T...
2.
[Retrospective study on smoking in lung cancer at the University Hospital of Liège]
Delvenne M, Bonhivers V, Seidel L, Delvenne P, Duysinx B, Jerusalem G, et al.
Rev Med Liege . 2024 Nov; 79(11):701-710. PMID: 39545530
This retrospective study including 93 patients who presented a new diagnosis of lung cancer at the University Hospital of Liege between January 2023 and April 2023 analyzed the prevalence of...
3.
The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity
Willems M, Hamaidia M, Fontaine A, Gregoire M, Halkin L, Vilanova Mana L, et al.
EBioMedicine . 2024 Oct; 109:105418. PMID: 39471751
Background: In mesothelioma (MPM), clinical evidence indicates that the absolute eosinophil count negatively correlates with overall survival and response to standard chemotherapy. Since eosinophils poorly infiltrate MPM tumours, we hypothesised...
4.
Identification of CT radiomic features robust to acquisition and segmentation variations for improved prediction of radiotherapy-treated lung cancer patient recurrence
Louis T, Lucia F, Cousin F, Mievis C, Jansen N, Duysinx B, et al.
Sci Rep . 2024 Apr; 14(1):9028. PMID: 38641673
The primary objective of the present study was to identify a subset of radiomic features extracted from primary tumor imaged by computed tomography of early-stage non-small cell lung cancer patients,...
5.
Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: A large single institution experience
Lucia F, Mievis C, Jansen N, Duysinx B, Cousin F, Louis T, et al.
Clin Transl Radiat Oncol . 2024 Jan; 45:100720. PMID: 38288310
Purpose: To evaluate the impact of dosimetric parameters on efficacy of stereotactic body radiation therapy (SBRT) in early-stage non-small cell lung cancer (ES-NSCLC), using Hypofractionated Treatment Effects in the Clinic...
6.
Multicentric development and evaluation of [F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body radiation therapy
Lucia F, Louis T, Cousin F, Bourbonne V, Visvikis D, Mievis C, et al.
Eur J Nucl Med Mol Imaging . 2023 Nov; 51(4):1097-1108. PMID: 37987783
Purpose: To develop machine learning models to predict regional and/or distant recurrence in patients with early-stage non-small cell lung cancer (ES-NSCLC) after stereotactic body radiation therapy (SBRT) using [F]FDG PET/CT...
7.
[Clinically amyopathic dermatomyositis : a rare entity associated with acute and severe interstitial lung disease]
Debrus C, Calmes D, von Frenckell C, Duysinx B, Cataldo D, Corhay J, et al.
Rev Med Liege . 2023 Aug; 78(7-8):441-447. PMID: 37560958
Dermatomyositis is a rare disease of unknown etiology characterized by a severe inflammatory myopathy associated with a cutaneous syndrome. Dermatomyositis is associated with multisystemic disorders mostly represented by cardiac, pulmonary...
8.
Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Cousin F, Louis T, Dheur S, Aboubakar F, Ghaye B, Occhipinti M, et al.
Cancers (Basel) . 2023 Apr; 15(7). PMID: 37046629
The aim of our study was to determine the potential role of CT-based radiomics in predicting treatment response and survival in patients with advanced NSCLC treated with immune checkpoint inhibitors....
9.
Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
Willems M, Scherpereel A, Wasielewski E, Raskin J, Brossel H, Fontaine A, et al.
Front Immunol . 2023 Apr; 14:1148798. PMID: 37026006
Background: Only a fraction of patients with malignant pleural mesothelioma (MPM) will respond to chemo- or immunotherapy. For the majority, the condition will irremediably relapse after 13 to 18 months....
10.
HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells
Hoyos C, Fontaine A, Jacques J, Heinen V, Louis R, Duysinx B, et al.
Cancers (Basel) . 2022 May; 14(9). PMID: 35565292
The composition of the tumor microenvironment (TME) mediates the outcome of chemo- and immunotherapies in malignant pleural mesothelioma (MPM). Tumor-associated macrophages (TAMs) and monocyte myeloid-derived immunosuppressive cells (M-MDSCs) constitute a...